Martek announces settlement of French patent dispute with Capsugel.
DHA omega-3 innovator and maker of the life's DHA brand, Martek Biosciences Corporation (Columbia, MD), resolved a patent dispute with Capsugel France. The resolution follows Martek's November 2008 action for infringement filed in the High Court of Strasbourg, France.
As a result of this settlement agreement between Martek and Capsugel France, Capsugel and all of its affiliates have agreed to purchase all of their algal DHA exclusively from Martek for the life of the patent in question. Additionally, Martek and Capsugel will develop a product containing Martek's algal DHA in Capsugel's proprietary Licaps liquid-filled hard capsules.
This settlement agreement between Martek and Capsugel does not include Martek's action against Lonza Ltd AG, which continues.
Martek Biosciences is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life's DHA, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and life's ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks.
Martek Biosciences Corporation
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief article|
|Date:||Aug 1, 2009|
|Previous Article:||RZN Nutraceuticals receives United States Patent and Trademark Office notice of allowance for proprietary HerbaZorb absorption and delivery.|
|Next Article:||Isis receives notice of allowance that expands the scope of key RNA therapeutic patents for single-stranded RNAi technology.|